Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New stomach cancer surgery technique shows promise in early trial

NCT ID NCT05545293

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to reconnect the stomach and small intestine after removing the lower part of the stomach in people with advanced stomach cancer. The goal was to see if the new stapling method was safe and worked well. One hundred patients took part, and the researchers tracked complications, recovery time, and quality of life after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Sep 2017

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All eligible patients enrolled in this study would undergo double-stapling end-to-end gastroduodenostomy Billroth-I anastomosis in laparoscopy-assisted surgery

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 18 to years (including 18 and 85years old) * Pathological diagnosis of primary focus is gastric adenocarcinoma made by endoscopic biopsy (papillary, tubular, mucinous, signet ring cell, poorly differentiated) * cT1-4a, N+/-, M0 at preoperative evaluation * No peritoneal metastasis or other distant metastases of gastric carcinoma (affirmed by laparoscopic surgery and related imaging examinations) * Expected curative resection through laparoscopic distal gastrectomy with D2 lymphadenectomy (include multiple primary lower gastric adenocarcinoma) * Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG) * Preoperative American Society of Anesthesiology score (ASA) classⅠ, Ⅱ or Ⅲ * Major organs are functioning normally: blood routine test (No blood transfusions in the last 14 days): HB≥90g/L, ANC≥1.5×109/L, PLT≥80×109/L blood biochemical examination: BIL\<1.5× upper limit of normal (ULN), ALT and AST\<2.5×ULN, Crea≤1×ULN. \- The subject is willing to participate in this clinical trail Exclusion Criteria: * History of previous upper abdominal surgery (include ESD/EMR, except laparoscopic cholecystectomy) * History of acute pancreatitis * Regional fusion of enlarged lymph nodes by preoperative imaging (maximum diameter \>3cm) * History of other malignant disease within past five years * History of unstable angina, myocardial infarction, cerebral infraction, or cerebral hemorrhage within past six months * History of continuous systematic corticosteroids therapy within past one month * Requirement of simultaneous surgery for other disease * Emergency surgery due to complication (bleeding, or perforation) caused by gastric cancer * FEV1\<50% of predicted values by pulmonary function test * Women during pregnancy or breast-feeding * Severe mental disorder * Participating in other clinical studies simultaneously * Refusing to sign the informed consent for the study * Peritoneal implant or other distant metastases by intraoperative exploration * Unresectable due to tumor reasons by intraoperative exploration * Distal gastric cancer surgery cannot be performed after intraoperative exploration * Duodenal bulb has been invaded by tumor or gastroduodenostomy cannot be performed due to additional surgical resection cause by positive intraoperative frozen margin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced gastric carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.